Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2020-07-27

Clinical Trial Update: IMCgp100-401 Rollover Study [Phase 2]

View source ↗

Summary

Phase 2 rollover study for IMCgp100 in malignant melanoma was terminated; results posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • IMCgp100 (tebentafusp)

Snippet

Sponsor: Immunocore Ltd | Conditions: Malignant Melanoma | Phase 2 | Status: TERMINATED | Results posted: 2020-07-27